The company announced the promotion of Neil Leatherbury to senior vice president, Head of Chemistry, Manufacturing and Controls reporting directly to Michael Amoroso, president and chief executive officer.
Leatherbury leads Precision's teams responsible for gene delivery, analytical development, process development, manufacturing, supply chain and manufacturing science and technology.
In addition, the company announced that Derek Jantz, Ph.D., Co-Founder and chief scientific officer, has announced his intentions to gradually step away from his current day-to-day responsibilities at the company to pursue other personal and professional interests while continuing to support the company's external relationships, including existing and potential business development partners. He will assume an advisory role as Co-Founder, chief science Advisor.
In this capacity, Dr. Jantz is expected to provide ongoing platform advice and support to the company's executive team, as well as the board of directors' Science and Technology Committee, while also providing continuity to ongoing collaborations and assisting with development of new partnerships.
Co-founder Jeff Smith, Ph.D. continues to lead the company's research strategy and day-to day management of the research function in his role as Chief Research officer, reporting directly to the CEO, as previously announced in September 2022.
In addition to these ongoing responsibilities, Jeff will assume primary leadership of the company's joint steering committees with Lilly and Novartis and will serve as the primary scientific lead for potential new business development partners.
Leatherbury joined Precision BioSciences in 2017 and has served in a variety of roles within Precision BioSciences' CMC organization, including his most recent role as the vice president of CMC.
Neil brings more than 25 years of life science experience to this role with experience in CMC operations, pharmaceutical development and product development.
Prior to joining Precision BioSciences, Neil worked at Mirna Therapeutics, Azaya Therapeutics, Smith & Nephew and Procter & Gamble.
Dr. Smith is one of the true pioneers in genome editing and has made some of the key observations that led to the first successful engineered editing nucleases.
Jeff received his graduate degree from Johns Hopkins University, where he developed and characterized custom nucleases for genome engineering.
Continuing his work in protein engineering at Duke University, Jeff helped create the foundation for Precision's ARCUS genome editing technology. He is an inventor on more than 75 foundational, issued patents involving the production and use of genome editing tools.
Precision BioSciences is a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS genome editing platform.
ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind.
Using ARCUS, the company's pipeline consists of multiple ex vivo "off-the-shelf" CAR T immunotherapy clinical candidates and several in vivo gene editing candidates designed to cure genetic and infectious diseases where no adequate treatments exist.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer